J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jung, D
Right arrow Articles by Dorr, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jung, D
Right arrow Articles by Dorr, A

Articles

Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects

D Jung and A Dorr

As a result of the low oral bioavailability of ganciclovir, a prodrug was developed to improve the bioavailability of ganciclovir. This study was designed to investigate the fasting, single-dose pharmacokinetics as well as the absolute and relative bioavailability of a valine ester prodrug of ganciclovir, valganciclovir, as compared to oral and intravenous ganciclovir in asymptomatic HIV+ and CMV+ subjects. In this open-label, randomized, three-period crossover study, 18 subjects received, in random order, single oral doses of valganciclovir 360 mg and ganciclovir 1000 mg and an intravenous infusion of ganciclovir 5 mg/kg over 1 hour. Valganciclovir was rapidly and extensively hydrolyzed to ganciclovir, resulting in significantly greater bioavailability compared to 1000 mg oral ganciclovir (60.9% vs. 5.6%, respectively). Higher peak serum concentrations were reached earlier following valganciclovir (ganciclovir [2.98 +/- 0.77 micrograms/mL at 1.0 +/- 0.3 h]) than following oral ganciclovir (0.47 +/- 0.17 microgram/mL and 2.2 +/- 1.0 h). Mean total ganciclovir AUCs following oral ganciclovir (1000 mg) and 360 mg valganciclovir (3.8 +/- 1.2 and 10.8 +/- 1.9 micrograms-h/mL) were less than that following a standard 5 mg/kg intravenous infusion of ganciclovir (25.1 +/- 3.8 micrograms-h/mL). In summary, valganciclovir is a prodrug with a favorable safety profile with enhanced bioavailability and significantly higher serum concentrations of ganciclovir than following oral administration of ganciclovir itself.


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
L. Lai, Z. Xu, J. Zhou, K.-D. Lee, and G. L. Amidon
Molecular Basis of Prodrug Activation by Human Valacyclovirase, an {alpha}-Amino Acid Ester Hydrolase
J. Biol. Chem., April 4, 2008; 283(14): 9318 - 9327.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Einsele, P. Reusser, M. Bornhauser, P. Kalhs, G. Ehninger, H. Hebart, Y. Chalandon, N. Kroger, B. Hertenstein, F. Rohde, et al.
Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation
Blood, April 1, 2006; 107(7): 3002 - 3008.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
H. Peyriere, E. Jeziorsky, A. Jalabert, M. Cociglio, A. Benketira, J.-P. Blayac, S. Hansel, G. Margueritte, and D. Hillaire-Buys
Neurotoxicity Related to Valganciclovir in a Child with Impaired Renal Function: Usefulness of Therapeutic Drug Monitoring
Ann. Pharmacother., January 1, 2006; 40(1): 143 - 146.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
E. Gershburg and J. S. Pagano
Epstein-Barr virus infections: prospects for treatment
J. Antimicrob. Chemother., August 1, 2005; 56(2): 277 - 281.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
Y. Huang, S. Ostrowitzki, G. Hill, M. Navarro, N. Berger, P. Kopeck, C. I. Mau, T. Alfredson, and R. Lal
Single- and Multiple-Dose Pharmacokinetics of Levovirin Valinate Hydrochloride (R1518) in Healthy Volunteers
J. Clin. Pharmacol., May 1, 2005; 45(5): 578 - 588.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
E. M. Lambert, J. Strasswimmer, R. Lazova, and R. J. Antaya
Cytomegalovirus Ulcer: Successful Treatment With Valganciclovir
Arch Dermatol, October 1, 2004; 140(10): 1199 - 1201.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Fortun Abete, P. Martin-Davila, S. Moreno, Y. Quijano, E. de Vicente, and L. Pou
Pharmacokinetics of Oral Valganciclovir and Intravenous Ganciclovir Administered to Prevent Cytomegalovirus Disease in an Adult Patient Receiving Small-Intestine Transplantation
Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2782 - 2783.
[Full Text] [PDF]

Home page
 NEJMHome page
D. F. Martin, J. Sierra-Madero, S. Walmsley, R. A. Wolitz, K. Macey, P. Georgiou, C. A. Robinson, M. J. Stempien, and the Valganciclovir Study Group
A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis
N. Engl. J. Med., April 11, 2002; 346(15): 1119 - 1126.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. D. Pescovitz, J. Rabkin, R. M. Merion, C. V. Paya, J. Pirsch, R. B. Freeman, J. O'Grady, C. Robinson, Z. To, K. Wren, et al.
Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients
Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2811 - 2815.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Clinical Pharmacology